Funded Startups in Nedlands
Five funded startups are listed in Nedlands, and the disclosed round sizes cluster tightly around single-digit and low-millions, except for one clear outli…
Five funded startups are listed in Nedlands, and the disclosed round sizes cluster tightly around single-digit and low-millions, except for one clear outlier: BARD1 Life Sciences raised $11M on 2021-07-23, dwarfing the next-largest disclosed amount of $7M (OncoRes Medical, 2022-05-18) and standing above the rest ($4M for My Mirror on 2024-12-01; $2M for Lixa on 2022-09-06). All five entries are in the same city (Nedlands, Western Australia) and the sector mix is also concentrated: four of five are Biotechnology (Argenica Therapeutics, Lixa, OncoRes Medical, BARD1 Life Sciences), with My Mirror the only Health Care outlier (Seed, 2024-12-01). Temporally, the rounds span 2021-07-23 to 2024-12-01, and three biotechnology rounds land within a 2022 window (2022-05-18, 2022-09-06, with Lixa and OncoRes).
Most recent rounds
5 shownRelated listings
Frequently asked
Which disclosed round is the outlier in Nedlands, and how does it compare to the other listed amounts?
BARD1 Life Sciences’ $11M on 2021-07-23 is the largest disclosed amount in the five-row set. The next-largest disclosed is OncoRes Medical at $7M (2022-05-18), while the remaining disclosed rounds sit at $4M (My Mirror, 2024-12-01) and $2M (Lixa, 2022-09-06), with Argenica Therapeutics the smallest at $840K (2023-01-20).
Are any sectors over-represented among these Nedlands-funded companies?
Biotechnology dominates with 4 of 5 entries: Argenica Therapeutics (2023-01-20, $840K), Lixa (2022-09-06, $2M), OncoRes Medical (2022-05-18, $7M), and BARD1 Life Sciences (2021-07-23, $11M). My Mirror is the only Health Care entry (Seed, 2024-12-01, $4M).
Do these rounds cluster in time, or are they spread evenly across the range?
The list spans 2021-07-23 through 2024-12-01, but there’s a noticeable 2022 cluster within biotechnology: OncoRes Medical closed on 2022-05-18 ($7M) and Lixa closed on 2022-09-06 ($2M). Outside that window, Argenica Therapeutics (2023-01-20, $840K) and My Mirror (2024-12-01, $4M) extend the timeline.
What does the stage mix suggest, and are there any stage labels that repeat?
Three different stage labels appear across the five rows: Seed (My Mirror, 2024-12-01, $4M), Series A (Lixa, 2022-09-06, $2M; OncoRes Medical, 2022-05-18, $7M), and Post-IPO Equity (BARD1 Life Sciences, 2021-07-23, $11M), plus one Series Unknown (Argenica Therapeutics, 2023-01-20, $840K). Series A is the only repeated stage, accounting for 2 of the 5 entries.
Are there very small or very recent rounds that stand out for follow-up?
The smallest disclosed round is Argenica Therapeutics at $840K on 2023-01-20, which is much lower than the rest of the disclosed amounts ($2M, $4M, $7M, and $11M). The most recent disclosed round is My Mirror at $4M on 2024-12-01.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.